Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 36, Octobre 2020
Les jeunes contre le cancer : la Ligue en soutien
|
|
|---|---|---|
| Page(s) | 56 - 60 | |
| DOI | https://doi.org/10.1051/medsci/2020194 | |
| Publié en ligne | 14 octobre 2020 | |
- Peréz-oler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining. J Clin Oncol 2005 ; 23 : 5235–5246. [CrossRef] [PubMed] [Google Scholar]
- Riechelmann H, Sauter A, Golze W, et al. Phase I trial with the CD44v6- targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008 ; 44 : 823–829. [CrossRef] [PubMed] [Google Scholar]
- Morgan RA, Yang JC, Kinato M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010 ; 18 : 843–851. [CrossRef] [PubMed] [Google Scholar]
- Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-pecific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5 : 207ra144. [PubMed] [Google Scholar]
- Trang VH, Zhang X, Yumul RC, et al. A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol 2019 ; 37 : 761–765. [CrossRef] [PubMed] [Google Scholar]
- Zhou F, Fu T, Huang Q, et al. Hypoxia-activated PEGylated conditional aptamer/antibody for cancer imaging with improved specificity. J Am Chem Soc 2019 ; 141 : 18421–18427. [Google Scholar]
- Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-pecific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5 : 207ra144. [PubMed] [Google Scholar]
- Mazor Y, Sachsenmeir KF, Yang C, et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep 2017 ; 7 : 1–11. [CrossRef] [PubMed] [Google Scholar]
- Slaga D, Ellerman D, Lombana TN, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med 2018; 10 : eaat5775. [PubMed] [Google Scholar]
- Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011 ; 11 : 671–677. [Google Scholar]
- Anemone A, Consolino L, Arena F, et al. Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH. Cancer Metastasis Rev 2019 ; 38 : 25–49. [CrossRef] [PubMed] [Google Scholar]
- Kodandapani L, Bookbinder LH, Frost GI, et al. Methods for assessing and identifying or evolving conditionally active therapeutic proteins. 2017; US9683985B2. [Google Scholar]
- Short JM, Chang HW, Frey G, et al. Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof. 2017; WO2017180842A1. [Google Scholar]
- Sulea T, Rohani N, Baardsnes J, et al. Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment. mAbs 2020; 12 : e1682866-1-15. [Google Scholar]
- Philibert P, Stoessel A, Wang W, et al. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 2007 ; 7 : 81. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.